Total Payments
$560,816
2024 Payments
$86,693
Companies
25
Transactions
384
Medicare Patients
42
Medicare Billing
$7,218
Payment Breakdown by Category
Research$423,874 (75.6%)
Other$78,400 (14.0%)
Travel$34,424 (6.1%)
Consulting$14,674 (2.6%)
Food & Beverage$9,337 (1.7%)
Education$107.51 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $423,874 | 69 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,400 | 37 | 14.0% |
| Travel and Lodging | $34,424 | 106 | 6.1% |
| Consulting Fee | $14,674 | 3 | 2.6% |
| Food and Beverage | $9,337 | 165 | 1.7% |
| Education | $107.51 | 4 | 0.0% |
Payments by Type
Research
$423,874
69 transactions
General
$136,943
315 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $439,729 | 108 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $53,106 | 71 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $38,041 | 56 | $0 (2022) |
| Lilly USA, LLC | $20,908 | 31 | $0 (2019) |
| Novo Nordisk AS | $2,861 | 10 | $0 (2018) |
| Mannkind Corporation | $1,477 | 12 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $1,349 | 11 | $0 (2023) |
| SANOFI US SERVICES INC. | $846.20 | 10 | $0 (2018) |
| Dexcom, Inc. | $603.44 | 39 | $0 (2023) |
| Medtronic MiniMed, Inc. | $376.90 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $86,693 | 16 | Eli Lilly and Company ($86,155) |
| 2023 | $17,948 | 74 | Eli Lilly and Company ($15,927) |
| 2022 | $98,118 | 50 | Eli Lilly and Company ($96,905) |
| 2021 | $752.09 | 7 | MannKind Corporation ($704.42) |
| 2020 | $13,105 | 6 | Eli Lilly and Company ($13,105) |
| 2019 | $19,225 | 24 | Eli Lilly and Company ($12,764) |
| 2018 | $219,584 | 120 | Eli Lilly and Company ($160,420) |
| 2017 | $105,392 | 87 | Eli Lilly and Company ($54,453) |
All Payment Transactions
384 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $53,199.00 | Research |
| Study: A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,329.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,300.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,788.00 | Research |
| Study: A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,439.00 | Research |
| Study: A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 09/23/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $124.90 | General |
| Category: LIVER DISEASE | ||||||
| 08/02/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Automated insulin delivery system | ||||||
| 06/28/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $146.13 | General |
| Category: Durable Pump | ||||||
| 06/25/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $41.71 | General |
| Category: DIABETES MEDICINE | ||||||
| 06/22/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $13.51 | General |
| 06/17/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $46.72 | General |
| Category: DIABETES MEDICINE | ||||||
| 06/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $48.41 | General |
| 06/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $42.68 | General |
| 04/16/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $351.71 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $145.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $145.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $65.73 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/25/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $25.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $132,238 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $54,395 | 3 |
| A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $53,199 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $49,559 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $29,164 | 2 |
| AN EXPLORATORY STUDY ASSESSING TIME IN TARGET GLUCOSE RANGE USING A NEW TITRATION SCHEME OF LY900014 AND INSULIN DEGLUDEC IN PATIENTS WITH TYPE 1 DIABETES | Eli Lilly and Company | $23,760 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $20,329 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $13,243 | 3 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $12,389 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $11,996 | 2 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $4,150 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $2,981 | 1 |
| A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) | Eli Lilly and Company | $2,439 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $2,050 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $1,682 | 3 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $1,503 | 2 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,434 | 2 |
| Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine | SANOFI-AVENTIS U.S. LLC | $1,277 | 10 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $947.39 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi | SANOFI US SERVICES INC. | $846.20 | 10 |
| INHALE-1 | Mannkind Corporation | $604.94 | 3 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $560.01 | 1 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $530.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $447.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $427.50 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES | Eli Lilly and Company | $388.88 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $291.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $210.30 | 1 |
| A PHASE 3B RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | Eli Lilly and Company | $206.91 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $142.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 24 | $2,949 | $2,224 |
| 2022 | 2 | 29 | 171 | $6,688 | $4,994 |
Total Patients
42
Total Services
195
Medicare Billing
$7,218
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 24 | $2,949 | $2,224 | 75.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 38 | $4,693 | $3,541 | 75.4% |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | Office | 2022 | 14 | 133 | $1,995 | $1,454 | 72.9% |
About Dr. Anuj Bhargava, MD
Dr. Anuj Bhargava, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Des Moines, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669563052.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anuj Bhargava, MD has received a total of $560,816 in payments from pharmaceutical and medical device companies, with $86,693 received in 2024. These payments were reported across 384 transactions from 25 companies. The most common payment nature is "" ($423,874).
As a Medicare-enrolled provider, Bhargava has provided services to 42 Medicare beneficiaries, totaling 195 services with total Medicare billing of $7,218. Data is available for 2 years (2022–2023), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Des Moines, IA
- Active Since 09/28/2006
- Last Updated 07/01/2014
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1669563052
Products in Payments
- SOLIQUA (Drug) $25,159
- BYDUREON (Drug) $22,801
- TOUJEO (Drug) $21,774
- FARXIGA (Drug) $15,129
- BASAGLAR (Drug) $11,758
- HUMULIN (Drug) $6,790
- SOLIQUA 100/33 (Drug) $6,135
- TRULICITY (Drug) $3,191
- AFREZZA (Drug) $1,477
- Tresiba (Drug) $1,316
- SAR439954 (Drug) $846.20
- Dexcom G6 Transmitter (Medical Supply) $558.97
- Minimed 670G System (Device) $376.90
- MINIMED 780G (Device) $328.63
- INVOKANA (Drug) $268.70
- RESMETIROM (Drug) $124.90
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $41.43
- MINIMED 770G (Device) $34.76
- DEXCOM CGM (Device) $31.62
- JARDIANCE (Drug) $28.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Des Moines
Teck Kim Khoo, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $26,928
Endocrinology, Diabetes & Metabolism $26,928
Nancy Kane, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $18,591
Endocrinology, Diabetes & Metabolism $18,591
Pierre Theuma, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,817
Endocrinology, Diabetes & Metabolism $1,817
Dr. Vanitha Singaram, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1,244
Endocrinology, Diabetes & Metabolism $1,244
Dr. Pearl Dy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $682.63
Endocrinology, Diabetes & Metabolism $682.63
Daniela Milani, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $672.19
Endocrinology, Diabetes & Metabolism $672.19